Dunia

Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

The Guardian · 48 menit lalu

Sumber: The Guardian · 48 menit lalu

Recap • TITIR

GLP-1 drugs like Ozempic and Mounjaro dominate weight-loss market, shifting focus from diabetes treatments.
Many poorer countries struggle to access basic diabetes care, including insulin.
Pharma firms are redirecting attention from insulin to weight-loss drugs.
The Access to Medicine Foundation head warns of supply risks for diabetes treatments.
Novo Nordisk and Eli Lilly lead GLP-1 drug production for obesity and diabetes.

Recap singkat dari artikel aslinya. Bisa aja kurang pas — baca sumber aslinya buat versi lengkap.